DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human-Relevant New Approach Methodologies (NAMs)

^
Dynamics Group AG / Schlagwort(e): Sonstiges
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0,
Advancing Human-Relevant New Approach Methodologies (NAMs)

24.12.2025 / 12:58 CET/CEST

---------------------------------------------------------------------------

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0,
Advancing Human-Relevant New Approach Methodologies (NAMs)

ZURICH/SCHLIEREN, Switzerland, December 24, 2025 - DiNABIOS AG, a global
leader in human-centric New Approach Methodologies (NAMs) for preclinical
research, today celebrates the U.S. Senate's passage of the FDA
Modernization Act 3.0 (FDAMA 3.0), a milestone in modernizing drug
development by enabling advanced, human-relevant nonclinical testing
methods.

The Act builds on prior modernization efforts by directing the U.S. Food and
Drug Administration (FDA) to establish clear qualification pathways for
NAMs, including advanced cell-based, microphysiological and in silico
systems. Together, these approaches promise improved predictivity, shorter
development timelines, and a meaningful reduction in animal testing.

"FDA Modernization Act 3.0 signals a transformative moment for science and
industry," said Dr. Alexandra Rhoden, CEO of DiNABIOS. "Regulatory alignment
creates opportunity, but adoption will ultimately be driven by scientific
rigor, reproducibility and human relevance, areas where DiNABIOS has made
sustained investments."

Dr. Marcel Grunert, COO of DiNABIOS, added: "This legislation validates the
industry's shift toward scalable, decision-ready NAM platforms. DiNABIOS is
well positioned to support pharmaceutical partners as these methods move
into core decision-making workflows."

Reto Wittwer, Chairman of DiNABIOS, commented: "Modernizing regulatory
frameworks is essential for innovation, efficiency and ethical
responsibility. This moment underscores the importance of companies that
combine scientific excellence with operational readiness - exactly what
DiNABIOS represents."

About DiNABIOS

DiNABIOS is an innovative life science company improving the predictivity
and efficiency of preclinical research from lab to life by integrating
advanced experimental and computational systems grounded in human cell and
tissue biology. For more information visit www.dinabios.com.

Contact

DiNABIOS AG
Wagistrasse 25
8952 Schlieren (Zurich)
Switzerland
contact@dinabios.com


---------------------------------------------------------------------------

Zusatzmaterial zur Meldung:

Datei:
https://eqs-cockpit.com/c/fncls.ssp?u=850673a75ba293d448f68bef14716148
Dateibeschreibung: Media Release DiNABIOS_FDA Modernization Act_2025

---------------------------------------------------------------------------

Ende der Medienmitteilungen
Originalinhalt anzeigen:
https://eqs-news.com/?origin_id=be391ca6-e0be-11f0-be29-0694d9af22cf&lang=de

---------------------------------------------------------------------------

2251462 24.12.2025 CET/CEST

°


Quelle: dpa-AFX